
    
      Lung cancer patients who received epidermal growth factor receptor tyrosine kinase
      inhibitors(EGFR-TKI) will acquiring resistance to the drug. This is a study of using
      Endostar, an angiogentic medicine, combination with chemotherapy and EGFR-TKI in lung cancer
      rechallenging treatment after resistance of EGFR-TKI and progression disease.
    
  